TD Asset Management Inc Sells 21,228 Shares of Scholar Rock Holding Corporation $SRRK

TD Asset Management Inc cut its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 6.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 312,398 shares of the company’s stock after selling 21,228 shares during the quarter. TD Asset Management Inc owned approximately 0.32% of Scholar Rock worth $11,634,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. AQR Capital Management LLC raised its stake in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after acquiring an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the last quarter. Millennium Management LLC boosted its stake in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after acquiring an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares during the period. Finally, Strs Ohio bought a new stake in shares of Scholar Rock during the 1st quarter valued at $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of SRRK opened at $44.27 on Monday. The stock has a 50 day simple moving average of $45.36 and a 200 day simple moving average of $38.91. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $49.82. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market capitalization of $4.52 billion, a PE ratio of -14.05 and a beta of 0.70.

Analyst Ratings Changes

SRRK has been the topic of several recent research reports. BMO Capital Markets restated an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research report on Friday, November 14th. HC Wainwright increased their target price on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Barclays upped their price target on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Citigroup initiated coverage on shares of Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 price objective on the stock. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $51.14.

Insider Activity at Scholar Rock

In other news, insider Caryn Parlavecchio sold 9,035 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $420,398.55. Following the sale, the insider directly owned 169,087 shares in the company, valued at $7,867,618.11. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mo Qatanani sold 8,484 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the transaction, the insider owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 344,932 shares of company stock valued at $15,371,225. 13.30% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).